May 21, 2025 08:26AM
Mar 19, 2025 09:25PM
Mar 19, 2025 09:25PM
Nov 12, 2024 07:00AM
Aug 8, 2024 07:00AM
Jun 27, 2024 07:00AM
May 14, 2024 07:00AM Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
May 9, 2024 07:01AM
May 9, 2024 07:00AM
Apr 25, 2024 07:01AM
Apr 25, 2024 07:00AM
Mar 15, 2024 03:35PM
Mar 15, 2024 03:34PM
Mar 7, 2024 07:00AM Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Jan 18, 2024 12:00PM
Dec 6, 2023 07:02AM
Dec 6, 2023 07:00AM
Nov 9, 2023 07:00AM
Aug 21, 2023 09:15AM
Aug 10, 2023 07:00AM
May 11, 2023 07:00AM Optinose Reports First Quarter 2023 Financial Results and Operational Updates
May 4, 2023 07:24AM
May 4, 2023 07:00AM
Mar 7, 2023 07:00AM
Feb 21, 2023 07:08AM
Feb 21, 2023 07:00AM
Jan 31, 2023 07:00AM
Dec 15, 2022 04:30PM OptiNose (OPTN) Appoints Paul Spence as Chief Commercial Officer
Dec 15, 2022 04:30PM
Nov 30, 2022 07:00AM
Nov 11, 2022 08:53AM
Nov 10, 2022 07:00AM
Nov 9, 2022 03:00PM
Oct 21, 2022 07:00AM
Sep 6, 2022 12:00PM Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
Aug 11, 2022 07:00AM
Jul 13, 2022 07:00AM
Jul 8, 2022 07:00AM
Jul 8, 2022 07:00AM
Jun 13, 2022 07:02AM
Jun 13, 2022 07:00AM
May 12, 2022 07:00AM Optinose Reports First Quarter 2022 Financial Results and Operational Updates
Mar 8, 2022 07:00AM
Mar 7, 2022 07:00AM
Mar 7, 2022 07:00AM
Nov 15, 2021 04:26PM
Oct 28, 2021 06:59AM
Aug 11, 2021 07:00AM
Jul 30, 2021 08:00AM Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
Jun 24, 2021 08:00AM

322,084 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All